Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?

NCT ID NCT03463408

NEW Completed Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This pilot trial is investigating whether giving two immunotherapy drugs, nivolumab and ipilimumab, along with radiation therapy before surgery can safely help treat soft tissue sarcoma. The study enrolls adults with resectable, intermediate-to-high grade sarcomas larger than 5 cm who are scheduled for preoperative radiation. The main goal is to evaluate the safety and side effects of this combination approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs) combined with radiation therapy
What this could lead to: If successful, this approach could offer a new way to shrink sarcomas before surgery, potentially improving outcomes and reducing recurrence risk.
What could go wrong: This is a very early, small pilot study focused on safety, so it may not show clear benefit. Combining immunotherapy with radiation can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, 14642-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.